NTLA-2001
Intellia Therapeutics
['cardio', 'cardiomyopathy', 'crispr']
intellia presents updated interim data from the cardiomyopathy arm of ongoing phase 1 study of ntla-2001, an investigational crispr therapy for the treatment of transthyretin (attr) amyloidosis at the american heart association scientific sessions 2022 
All in on $BEAM and $NTLA. Looking for 10x in 3-5 years (6/13/22). Believe BEAM will eventually become most valuable #biotech in the world ?? #CRISPR #longevity